Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.
about
Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in ChildrenMethodological challenges in measuring vaccine effectiveness using population cohorts in low resource settingsPrevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesEpidemiology, virulence factors and management of the pneumococcusThe host immune dynamics of pneumococcal colonization: implications for novel vaccine developmentThe potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experienceChallenges to estimating vaccine impact using hospitalization data.Early trends in invasive pneumococcal disease in children following the introduction of 13-valent pneumococcal conjugate vaccine: results from eight years of active surveillance in a Mexican hospital.All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.Comment on: "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children".Reply to Farkouh RA et al. Comment on "Cost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-Typeable Haemophilus Influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese Children"Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review.Methods and challenges for the health impact assessment of vaccination programs in Latin AmericaSurveillance of the impact of pneumococcal conjugate vaccines in developing countriesCost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.Changes in the incidence of pneumonia, bacterial meningitis, and infant mortality 5 years following introduction of the 13-valent pneumococcal conjugate vaccine in a "3+0" schedule.Pneumococcal conjugate vaccine use in adults.The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia.Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.Pneumococcal conjugate vaccines and hospitalization of children for pneumonia: a time-series analysis, South Africa, 2006-2014.Impact of pneumococcal conjugate vaccines for children in high- and non-high-income countries.Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children.Challenges in the Surveillance of Invasive Pneumococcal Disease in the Postvaccination Era.Burden of hospitalized childhood community-acquired pneumonia: A retrospective cross-sectional study in Vietnam, Malaysia, Indonesia and the Republic of Korea.
P2860
Q26782280-6217FE65-8DFD-4D2F-BD6B-90B1AE8639B7Q26800157-D6BBEC9D-904C-4D9F-9E8C-F2E782D39DCAQ28077703-2FD78EE5-2693-4C93-B57B-B09F40AA649DQ28078832-0C70F469-5BAC-4B4E-AF0D-A3A274B67E6BQ28084920-F3B8DEC0-213D-49AD-9E6E-023E9CC4A0C4Q28088507-ACF3B98E-7A60-480B-B310-7A92B07A5FC3Q31145427-DA97D720-1132-4AC0-AFCD-AD8643A7AB78Q34418768-8A955776-C621-40FD-8D61-A9A4BF54EA51Q34473127-8102B994-175F-4E72-B34C-B7C50B73171BQ35752767-8887F36C-E928-4147-82D9-6B7CFC9A888EQ35752770-A7484CFE-5E73-4606-8B74-A648357EFBBBQ36219932-A970F826-B1EE-40A5-95E6-877BBE6FFE33Q36395006-DF756298-0485-413A-91C1-FD23A3528888Q37309181-339CAED7-5989-4AD6-8D89-BC273B33A611Q37309195-CE985CCC-A927-4545-A899-D684EEE539CAQ38622148-9B42A3B4-DDB8-4EF7-82E4-BE211BB3583AQ38664425-3537B387-959D-4B6E-988C-C6CC9348F10AQ38682463-A6154A73-AB9C-4E22-B162-C0F57FE8C2A8Q38956348-7BDFF0D2-ECFD-4ABB-A04E-E71126227D89Q39200736-010D09E2-D851-44CD-B463-FE91A146F4CBQ40059651-D3F989F8-32E6-4B61-9B85-05A32E91CEDDQ40242598-60FC9C2C-7101-4B0C-A66F-A617F708339BQ40401092-C9B0A9B5-B6D3-4A1B-84B0-FF9525D0F25BQ40500473-B319E246-DA83-4E55-B564-33E6A8DDD2ECQ48324606-33163870-4FD8-4C72-A7AD-FAC24841E884
P2860
Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@en
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@nl
type
label
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@en
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@nl
prefLabel
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@en
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@nl
P2093
P1476
Changes in childhood pneumonia ...... onjugate vaccine in Nicaragua.
@en
P2093
Christopher W Woods
David J Weber
Erick Amaya
Gilberto Moreno
Jorge Alemán
Julio Rocha
Michael G Hudgens
Rafaela Briceño
P304
P356
10.1097/INF.0000000000000269
P577
2014-06-01T00:00:00Z